Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
about
NAFLD and Chronic Kidney DiseaseSulforaphane and Other Nutrigenomic Nrf2 Activators: Can the Clinician's Expectation Be Matched by the Reality?The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease.Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: biochemical, pharmacological and toxicological implicationsBardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.Emerging drugs for chronic kidney disease.Aldosterone activates transcription factor Nrf2 in kidney cells both in vitro and in vivoOleanane triterpenoids in the prevention and therapy of breast cancer: current evidence and future perspectives.Dual roles of NRF2 in tumor prevention and progression: possible implications in cancer treatmentAntioxidants in kidney diseases: the impact of bardoxolone methyl.Reduction of microalbuminuria in type-2 diabetes mellitus with angiotensin-converting enzyme inhibitor alone and with cilnidipineUrsolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironmentThe extinguished BEACON of bardoxolone: not a Monday morning quarterback story.Novel drugs and intervention strategies for the treatment of chronic kidney disease.The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction.The Nrf2 pathway in the progression of renal disease.Triterpenoid inducers of Nrf2 signaling as potential therapeutic agents in sickle cell disease: a review.Are reactive oxygen species still the basis for diabetic complications?Bardoxolone-methyl inhibits migration and metabolism in MCF7 cells.Novel avenues for treating diabetic nephropathy: new investigational drugs.Diabetic Microvascular Disease: An Endocrine Society Scientific Statement.Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.Activation of Nrf2 signaling by natural products-can it alleviate diabetes?Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.Oxidative Stress and Renal Fibrosis: Recent Insights for the Development of Novel Therapeutic Strategies.
P2860
Q26752759-B29E12CC-DA9F-49EF-99EE-9A215B29594AQ26765790-45F00E1A-FCE0-450D-AFC1-F96BF08639F0Q33716356-DD083D8C-327B-4C4B-9CBB-0EA4566DA58FQ33970540-28566852-3C59-4458-AB88-C8F8BE1D05AEQ34383685-46F1BE06-E504-489F-9450-AFC50F325431Q34420383-EB3D9C1F-BCC1-4503-8759-E8313DF51413Q34431544-0841FE23-DF5D-484A-B149-0095CD5C4B92Q34479307-09B32013-0147-46A1-9CFF-FF1FD7526E07Q35118710-576DA3EF-D2F5-4115-B992-F16E29EB77EDQ36026304-C5F6EF54-B398-4E37-87D9-B2F23A27AE8FQ36330445-9E7A0530-87EF-4DF2-BE93-B676933B468CQ37022420-8AE25942-08B7-43DF-BC7B-5EE4101021C3Q37050229-34A9F6D3-D782-4349-8E0F-115B58E67817Q37219043-FF977C67-481D-4E1C-B68B-228EAA26E60EQ37679215-F2A69B82-5B3E-43F5-9CE2-3BA86993DEABQ38114031-EC97A36F-A9F5-4B85-95D9-811EC07C3261Q38289589-16C3155E-7F65-42B5-AFC5-8633F88C2D1DQ38451253-8CF682FF-C9B9-4193-A822-A9A176182391Q38712952-FE839DF7-99AA-4207-A91B-28A41A27C532Q39170387-A905C9B0-878C-470C-9F68-D162AE997AADQ45072634-C89B52D9-9CAC-4089-A890-C334985A378CQ47117016-D27B5DC3-B622-4493-B5D6-B7C62C1779CAQ49385295-787CAC37-961E-49E9-8950-F9768BA6C514Q50198506-8C877F51-3FAF-4277-8D41-9C3F639680EAQ52674866-BC00E219-832F-4694-9997-26CBBBD0232E
P2860
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Rationale and trial design of ...... ence of Renal Events (BEACON).
@en
Rationale and trial design of ...... the Occurrence of Renal Events
@nl
type
label
Rationale and trial design of ...... ence of Renal Events (BEACON).
@en
Rationale and trial design of ...... the Occurrence of Renal Events
@nl
prefLabel
Rationale and trial design of ...... ence of Renal Events (BEACON).
@en
Rationale and trial design of ...... the Occurrence of Renal Events
@nl
P2093
P2860
P50
P356
P1476
Rationale and trial design of ...... ence of Renal Events (BEACON).
@en
P2093
Christoph Wanner
Colin J Meyer
David G Warnock
Dick de Zeeuw
George L Bakris
Glenn M Chertow
Hans-Henrik Parving
Hiddo J Lambers Heerspink
Melanie Chin
Melissa Krauth
P2860
P304
P356
10.1159/000346948
P577
2013-02-28T00:00:00Z